Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam pretreatment for prevention of propofol injection pain during gastroscopy
ChiCTR2200065866Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of remimazolam, propofol, lidocaine and esketamine (4 arms), sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoint: Incidence of propofol-induced injection pain. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
remimazolampropofollidocaineesketamine
Beyond the preview
Go deeper on ChiCTR2200065866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065866.